HAS-BLED: Atrial fibrillation patients undergoing angioplasty can still take anticoagulants

By Piriya Mahendra

Researchers say that oral anticoagulation could improve the prognosis of atrial fibrillation (AF) patients who undergo percutaneous coronary intervention (PCI), even if they have a high bleeding risk according to the HAS-BLED score.

It has previously been suggested that the HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly [<65 years], Drugs/Alcohol concomitantly) score may be used to assess bleeding risk in patients with AF. However, until now, it has not been tested in those undergoing PCI.

Gregory Lip (University of Birmingham, UK) and colleagues found that of the 590 AF patients undergoing PCI in their study with a CHA2DS2-VASC of more than 1 (indicating anticoagulation is required), 420 (71%) had a high risk for bleeding, as indicated by a HAS-BLED score of 3 or more.

Of the whole cohort, 56% received anticoagulation at discharge. These patients had a significantly lower mortality rate, at 9.3% versus 20.1%, than those who did not receive it (p<0.01).

They also had a lower rate of major adverse cardiac events (MACE; defined as death, acute myocardial infarction, or target vessel failure) than those who did not receive oral anticoagulation at discharge, at 13.0% versus 26.4% (p<0.01).

The two groups of patients had a similar rate of major adverse events (MACE, major bleeding, or thromboembolism). However, anticoagulated AF patients had a significantly higher major bleeding rate than those who were not anticoagulated, at 11.8% versus 4.0% (p<0.01).

Multivariate analysis revealed that chronic renal failure and the use of drug-eluting stents were significant predictors for major bleeding (p<0.04). Oral anticoagulation was associated with an 80% reduced risk for mortality (p<0.01).

The authors say their findings show that the HAS-BLED score as well as the more conventionally used CHA2DS2-VASC score can be used to stratify risk for mortality and cardiac events in AF patients who undergo PCI.

"Management decisions in these high-risk patients should be individualized (eg, using both CHA2DS2-VASC and HAS-BLED scores as per guidelines) with the need for careful clinical review and regular follow-up," they comment in Circulation: Cardiovascular Interventions.

"A randomized trial is warranted to study this complex population."

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
GLP-1 and SGLT2 inhibitors show promise in preventing recurrent stroke and heart attack